BRL Biotech, CAR T-Cell, CARsgen Therapeutics, China CAR T Cell, IASO Biotherapeutics, Juventas Therapeutics, Relma-cel
How China is leading the development of CAR T-Cell therapy?
March 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic effect or cures disease by repairi..
anti-BCMA, CAR - T Cell therapy, CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, orphan drug designation
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
CAR - T Cell therapy, China, IASO Biotherapeutics, multiple myeloma
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy designations from the U.S. Food and..